Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.38 |
| ▸ | TNF | P01375 | 1/20 | 0.37 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.36 |
| ▸ | CCNC | P24863 | 1/20 | 0.36 |
| ▸ | CDK8 | P49336 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.35 |
| ▸ | CDK9 | P50750 | 1/20 | 0.35 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.33 |
| ▸ | SLC22A12 | Q96S37 | 2/20 | 0.33 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10526908 | 0.84 | HTT (0.42) | HTTKMT2AMEN1NCOA3TNF | |
| SCHEMBL3670639 | 0.81 | TNF (0.40) | HTTKMT2AMEN1TNFCCNC | |
| SCHEMBL37676938 | 0.81 | TNF (0.40) | HTTKMT2AMEN1TNFCCNC | |
| SCHEMBL23674615 | 0.80 | HTT (0.42) | HTTKMT2AMEN1NCOA3CYP19A1 | |
| SCHEMBL4544610 | 0.80 | CCNC (0.49) | HTTKMT2AMEN1NCOA3CYP19A1 | |
| SCHEMBL7662114 | 0.80 | HTT (0.42) | HTTKMT2AMEN1NCOA3CYP19A1 | |
| SCHEMBL15467814 | 0.77 | HTT (0.40) | HTTKMT2AMEN1NCOA3CYP19A1 | |
| SCHEMBL7213436 | 0.77 | CYP2E1 (0.47) | HTTKMT2AMEN1NCOA3CYP19A1 | |
| SCHEMBL17807363 | 0.76 | GAA (0.38) | KMT2AMEN1TNFCCNCCDK8 | |
| SCHEMBL21689084 | 0.76 | CYP17A1 (0.40) | HTTTNFCYP11B1CYP11B2CCNC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117069717-A | 2, 6-naphthyridine micromolecule derivative and preparation method thereof | 江汉大学 | 2023-11-17 | — | — | CN | disclosed |
| WO-2022263531-A1 | ACTIVE-MATRIX OLED DISPLAY | NOVALED GMBH (DE) | 2022-12-22 | — | — | WO | disclosed |
| EP-4106027-A1 | ACTIVE-MATRIX OLED DISPLAY | Novaled GmbH (DE) | 2022-12-21 | — | — | EP | disclosed |
| CN-108752296-A | A kind of five-ring heterocycles derivative and its organic electroluminescence device | 长春海谱润斯科技有限公司 | 2018-11-06 | — | — | CN | disclosed |
| US-7786177-B2 | Phenylalanine enamide derivatives | UCB PHARMA S.A. (BE) | 2010-08-31 | — | — | US | disclosed |
| US-7645770-B2 | Phenylalanine enamide derivatives | UCB PHARMA S.A. (BE) | 2010-01-12 | — | — | US | disclosed |
| US-20090186914-A1 | Phenylalanine Enamide Derivatives | UCB PHARMA, S.A. (BE) | 2009-07-23 | — | — | US | disclosed |
| US-7557130-B2 | Bicyclic heteroaromatic alanines | UCB PHARMA, S.A. (BE) | 2009-07-07 | — | — | US | disclosed |
| US-7531549-B2 | Phenylalanine enamide derivatives | UCB PHARMA, S.A. (BE) | 2009-05-12 | — | — | US | disclosed |
| US-20090105291-A1 | Phenylalanine Enamide Derivatives | RIGEL PHARMACEUTICALS, INC. (US) | 2009-04-23 | — | — | US | disclosed |
| US-20020169336-A1 | Phenylalanine enamide derivatives | UCB PHARMA S.A. (BE) | 2002-11-14 | — | — | US | disclosed |
| WO-2002068393-A1 | PHENYLALANINE ENAMIDE DERIVATIVES POSSESSING A CYCLOBUTENE GROUP, FOR USE AS INTEGRIN INHIBITORS | CELLTECH R & D LIMITED (GB) | 2002-09-06 | — | — | WO | disclosed |
| US-20020072607-A1 | Inhibit binding of integrins to their ligands and are of use in prophylaxis and therapy of of immune or inflammatory disorders, or disorders including inappropriate growth or migration of cells | CELLTECH R&D, LTD. (GB) | 2002-06-13 | — | — | US | disclosed |
| US-20020037909-A1 | Enamine derivatives | UCB PHARMA S.A. (BE) | 2002-03-28 | — | — | US | disclosed |
| WO-2002020522-A1 | BICYCLIC ENAMIDE DERIVATIVES BEING INTEGRIN INHIBITORS | CELLTECH R & D LIMITED (GB) | 2002-03-14 | — | — | WO | disclosed |
| EP-1181266-A1 | SQUARIC ACID DERIVATIVES AS CELL ADHESION MOLECULES | Celltech R&D Limited (GB) | 2002-02-27 | — | — | EP | disclosed |
| WO-2001079173-A2 | ENAMINE DERIVATIVES AS CELL ADHESION MOLECULES | CELLTECH R & D LIMITED (GB) | 2001-10-25 | — | — | WO | disclosed |
| WO-2000073260-A1 | SQUARIC ACID DERIVATIVES AS CELL ADHESION MOLECULES | CELLTECH R&D LIMITED (GB) | 2000-12-07 | — | — | WO | disclosed |
| US-4801590-A | ANGINA, ANTICANCER, CARDIOVASCULAR DISORDERS, HEADACHES, PSORIASIS, ASTHMA, ANTICOAGULANTS | BEIERSDORF AG (DE) | 1989-01-31 | — | — | US | disclosed |
| EP-0253171-A1 | Pyrido[1,8]naphthyridinones, process for their preparation and their use and compositions containing them | Beiersdorf-Lilly GmbH (DE) | 1988-01-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020037909-A1 | Enamine derivatives | CCR1, ITGB2, CCR10 | HTT 3826/4885KMT2A 3381/4885MEN1 4755/4885 |
| US-20020072607-A1 | Inhibit binding of integrins to their ligands and are of use in prophylaxis and therapy of of immune or inflammatory disorders, or disorders including inappropriate growth or migration of cells | ITGB2, VCAM1, ITGB1 | HTT 4464/4885KMT2A 3406/4885MEN1 4146/4885 |
| US-20090105291-A1 | Phenylalanine Enamide Derivatives | PAH, HRH3, PRLHR | HTT 4303/4885KMT2A 2235/4885MEN1 4566/4885 |
| US-20020169336-A1 | Phenylalanine enamide derivatives | CCR1, AHR, PAH | HTT 3609/4885KMT2A 1917/4885MEN1 4823/4885 |
| US-20090186914-A1 | Phenylalanine Enamide Derivatives | PAH, HRH3, PRLHR | HTT 4303/4885KMT2A 2235/4885MEN1 4566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.